07:00 , Oct 31, 2011 |  BC Week In Review  |  Company News

Accium BioSciences Inc., PrognosDx deal

The companies partnered to develop and commercialize predictive histone biomarkers tests using PrognosDx's epigenetic technology with Accium's accelerator mass spectrometry technology. Details were not disclosed. Accium BioSciences Inc., Seattle, Wash.   PrognosDx Health Inc., Palo Alto,...